Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antibody”

426 pharma patents match "antibody" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 426
Index total 30,257
Page 2 / 18

Quick answer

This filtered view shows 426 pharmaceutical patents matching "antibody" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

426 results for “antibody” · 30,257 patents in full index Clear search

  1. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  2. US 12319743

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  3. US 12319729

    Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  4. US 12311030

    Antibody-sting agonist conjugates and their use in immunotherapy

    The Board of Regents of the University of Texas System · Granted May 27, 2025 · Expires May 22, 2045

    granted
  5. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted May 20, 2025 · Expires May 15, 2045

    granted
  6. US 12304964

    CD38 modulating antibody

    BLACK BELT THERAPEUTICS LIMITED · Granted May 20, 2025 · Expires May 15, 2045

    granted
  7. US 12296013

    Photosensitizing antibody-fluorophore conjugates

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 13, 2025 · Expires May 8, 2045

    granted
  8. US 12290505

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  9. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  10. US 12286479

    Treatment with anti-α4β7 antibody

    Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  11. US 12280124

    Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  12. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  13. US 12263225

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  14. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  15. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  16. US 12234294

    Pharmaceutical composition of a humanized anti-CD40 antibody

    Kiniksa Pharmaceuticals, GmbH · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  17. US 12234295

    Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

    AUTOLUS LIMITED · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  18. US 12226490

    Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class

    Sutro Biopharma, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  19. US 12226524

    Coated implants for long-term controlled release of antibody therapeutics

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  20. US 12221460

    Antibody drug conjugates

    Takeda Pharmaceutical Company Limited · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  21. US 12188005

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  22. US 2025002606

    Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

    BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

    granted
  23. US 12180277

    LILRB4-binding antibody and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  24. US 12173078

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted